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Normal human keratinocytes (KC) are a prominent
source of vascular endothelial growth factor (VEGF)/
vascular permeability factor (VPF), both in vivo and in
tissue culture. In this report we have investigated the
influence of retinoids, which are used to treat several skin
diseases, on VEGF/VPF production by KC. All-trans
retinoic acid (RA), 13-cis RA, and all-trans retinol
reduced VEGF/VPF secretion by KC in primary cultures
by a mean K SD of 58 K 25%, 46 K 21%, and 54 K 20%,
respectively, compared with control values. Reductions
were observed at concentrations as low as 10–10 M for all-
trans RA, a level that is easily reached in vivo during
retinoid treatment. The reduction in VEGF/VPF protein
Vascular endothelial growth factor (VEGF) is a basic,heparin-binding glycoprotein that occurs in four iso-forms that include 121, 165, 189, and 201 amino acids,respectively (Houck et al, 1991; Tischer et al, 1991).Besides acting as a potent mitogen for endothelial cells
in vivo and in vitro, and playing a central role in angiogenesis, VEGF
increases microvascular permeability; hence, it is also referred to as
vascular permeability factor (VPF) (for review see Dvorak et al, 1995;
Ferrara and Davis-Smyth, 1997).
We and others have shown that normal human epidermal keratino-
cytes (KC) express the three major splice variants of VEGF/VPF in vitro
(Detmar et al, 1994; Ballaun et al, 1995) and in vivo (Weninger et al,
1996). Upregulation of VEGF/VPF mRNA and protein in vivo is
known to occur during wound healing (Brown et al, 1992), and in
psoriasis (Detmar et al, 1994), contact dermatitis, bullous skin diseases
(Brown et al, 1995a, b), common warts, and squamous cell carcinomas
(Weninger et al, 1996). Rather than representing a secondary phenom-
enon, KC-derived VEGF/VPF probably contributes actively to the
pathogenesis of these diseases via the induction of permeability in
dermal vessels, through its chemotactic action on inflammatory cells
and endothelial cells (Clauss et al, 1990; Koch et al, 1994; Gruber et al,
1995) and through its angiogenic effect.
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by 10–6 M all-trans RA was paralleled by a strong down-
regulation of VEGF/VPF mRNA levels. In contrast to
normal KC, all-trans RA had no effect on the HaCaT
keratinocyte cell line, and it stimulated VEGF/VPF
release by the epidermoid carcinoma cell line A431 2-fold.
Our data demonstrate that retinoids are potent inhibitors
of VEGF/VPF production by normal human KC. Down-
regulation of VEGF/VPF production in these cells by
retinoids may contribute to the therapeutic effects or
retinoids in diseases that are accompanied by angiopro-
liferation, such as psoriasis. Key words: angiogenesis/cyto-
kines/endothelial cells/psoriasis. J Invest Dermatol 111:907–
911, 1998
Its central role in angiogenesis makes VEGF/VPF an important
target for pro- and anti-angiogenic therapy. Concerning the regulation
of VEGF/VPF expression, various stimuli, including hypoxia and
exposure to certain cytokines such as epidermal growth factor, trans-
forming growth factor-α (TGFα), and interleukin-6, have been found
to upregulate VEGF/VPF production (Dvorak et al, 1996; Ferrara and
Davis-Smyth, 1997). Suppression of VEGF/VPF expression has so far
only been observed for corticosteroids (Harada et al, 1994; Palacio
et al, 1997).
Systemic administration of retinoids is used widely to treat psoriasis,
ichthyoses, acne, and rosacea, and topical administration has been used
to treat acne and photoaging. In addition to a variety of other biologic
activities, including effects on differentiation and proliferation of KC
(for extensive reviews see Chambon, 1996; Fisher and Voorhees,
1996), retinoids have been shown to inhibit angiogenesis in several
experimental systems. They are able to abrogate tumor-associated
angiogenesis in vivo (Majewski et al, 1994), switch the phenotype of
tumor cells in vitro from angiogenic to anti-angiogenic (Lingen et al,
1996a), and inhibit vessel ingrowth into the chorioallantoic membrane
of the chick (Oikawa et al, 1989, 1993). Such anti-angiogenic effects
of retinoids may result from altered endothelial cells activities, such as
the inhibition of endothelial cell migration (Lingen et al, 1996b), as
well as from modulated production of factors that stimulate or inhibit
vessel growth (Lingen et al, 1996b).
VEGF/VPF overproduction by KC has been implied in the charac-
teristic vascular changes commonly observed in psoriasis (Detmar et al,
1994). Because retinoids are a mainstay of anti-psoriatic therapy, we
examined their effects on VEGF/VPF production by KC. In this
report we demonstrate that all-trans retinoic acid (RA), 13-cis RA,
and all-trans retinol suppress secretion of VEGF/VPF by KC in primary
cultures, but not by KC-derived cell lines.
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MATERIALS AND METHODS
Cell culture Human neonatal foreskin KC derived from five different donors
were purchased from PromoCell (Heidelberg, Germany) or Clonetics (San
Diego, CA). KC were cultured under low-Ca21 conditions (0.15 mM) in
serum-free KC growth medium consisting of KC basal medium (KBM)
supplemented with human recombinant epidermal growth factor (0.1 ng per
ml), bovine pituitary extract, insulin (5 µg per ml), hydrocortisone (0.5 µg per
ml), and gentamycin/amphotericin B (50 µg per ml, 50 ng per ml) (all from
either PromoCell or Clonetics) at 37°C in 5% CO2. Cells were routinely
passaged at 60%–80% confluence using each manufacturer’s detachment solution
(0.05% trypsin/0.01% ethylenediamine tetraacetic acid). All experiments were
carried out between passages 2 and 5.
The epidermoid carcinoma cell line A431, the immortalized keratinocyte
cell line HaCaT (passage number . 35) were grown in RPMI-1640 supple-
mented with 10% fetal bovine serum and 1% L-glutamine (all GIBCO BRL,
Gaithersburg, MD).
Retinoids All-trans RA, 13-cis RA, and all-trans retinol were purchased
from Sigma (St. Louis, MO). Stock solutions were prepared in dimethylsulfoxide
(DMSO, 10–2 M) and stored protected from light at –20°C. At the time
of use, working solutions were prepared with KBM or with RPMI-1640
supplemented with 2 mM L-glutamine.
Stimulation experiments For all experiments, 3 3 105 primary KC were
seeded into 6 well plates (Costar, Cambridge, MA) in 2 ml of KC growth
medium and allowed to attach overnight. After 12–16 h, KC growth medium
was changed to either KBM or KBM supplemented with TGFα (100 ng per
ml, PBH, Hannover, Germany), with various concentrations of the respective
retinoids, with TGFα plus all-trans RA, or with DMSO alone.
For experiments with the cell lines, 3 3 105 cells were allowed to attach
overnight in RPMI-1640/10% fetal bovine serum. Then the medium was
changed to RPMI-1640, without fetal bovine serum, containing the indicated
reagents.
Supernatants were collected after 24 h and centrifuged sequentially at 700
and 17,600 3 g to remove cellular debris. The supernatants were stored frozen
at –20°C until further analysis.
Assessment of cytotoxicity and cell proliferation After collecting the
supernatants, cells were detached and viability tested with Trypan-blue. Cell
proliferation was assessed with the colorimetric assay EZ4U as described by the
manufacturer (Biomedica, Vienna, Austria). This test measures the reduction of
tetrazolium salts into intensely colored formazan derivatives, which occurs only
in living cells (Scudiero et al, 1988). Briefly, 1 3 104 cells were seeded into 96
well plates with KBM or KBM plus stimulants. Four hours prior to measurement,
the tetrazolium-salt was added. Extinction of the cell culture supernatant was
measured on an enzyme linked immunosorbent assay (ELISA) reader.
VEGF/VPF immunoassay Cell culture supernatants were analyzed using a
commercial VEGF-ELISA kit (CYTElisa-VEGF, CYTimmune Sciences,
College Park, MD) according to the manufacturer’s instructions.
Northern blot analysis KC were cultured at 60% confluence in 25 cm2
culture flasks (Costar) in either KBM or KBM supplemented with TGFα
(100 ng per ml), 0.01% DMSO, or all-trans RA at several concentrations. After
4 or 8 h cells were lyzed and total RNA extracted using the RNAzol B method
(CINNA/Biotecx Lab, Houston, TX). RNA was size fractionated in 1% agarose
gels containing 1.48% formaldehyde and transferred to nylon membranes
(Nytran, Schleicher and Schu¨ll, Dassel, Germany). Northern hybridization with
either a VEGF/VPF or a GAPDH cDNA probe was performed under stringent
conditions as described previously (Weninger et al, 1996).
Statistical analyses Treatment effects on KC in primary cultures were
compared by analysis of variance. The Student’s t test was used to calculate
differences in the cell line experiments. Significance was established at the level
of p , 0.05.
RESULTS
Effects of retinoids on the proliferation and viability of KC in
primary culture and of KC-derived cell lines The addition of
all-trans RA, 13-cis RA, or all-trans retinol to KC cultures at
concentrations . 10–5 M lead to significant cell death within 24 h.
Below 10–5 M, cell viability remained above 95% and cell morphology,
as judged by light microscopy, was not altered, i.e., the primary
keratinocytes appeared small and cobblestone-shaped (Boyce and Ham,
1983). All subsequent experiments were performed at retinoid concen-
trations of 10–6 M or less. Using a colorimetric proliferation assay, we
found that KC proliferative activity stayed within a range of 610%
when cells cultured in KBM were compared with those cultured in
KBM supplemented with the respective retinoids or DMSO, con-
firming previous studies (data not shown, Varani et al, 1989). In some
experiments, these data were also confirmed by manual cell counts
and measurement of total cellular protein. Also, no effect was observed
on the proliferation of A431 cells and HaCaT cells (data not shown).
Retinoids suppress VEGF/VPF secretion by KC in primary
cultures TGFα, a well-known inducer of VEGF/VPF secretion in
KC, was used as a positive control in each experiment. The mean 6
SD stimulatory effect of TGFα as compared with medium alone was
333% 6 152% (p , 0.001, data not shown). Incubation of KC with
all-trans RA resulted in a dose-dependent reduction of VEGF/VPF in
culture supernatants as assessed by ELISA. A typical dose-response
curve is shown in Fig 1(a). Strong reduction of VEGF/VPF secretion
by KC was observed with concentrations of all-trans RA equal to and
below 10–6 M. A total of 13 individual experiments with 10–6 M all-
trans RA was carried out, of which seven were run in triplicate. All-
trans RA suppressed VEGF/VPF production to a mean 6 SD of
58 6 25% compared with the DMSO control (p , 0.001). Similar
data were obtained when 13-cis RA (five individual experiments) or
all-trans retinol (four individual experiments) were examined (Fig 1b),
i.e., VEGF/VPF levels were reduced to 46 6 21% (p , 0.001) and
54 6 20% (p , 0.001) of control values, respectively.
To determine whether retinoids also influenced TGFα-induced
upregulation of VEGF/VPF secretion, KC were incubated simul-
taneously with TGFα (100 ng per ml) and all-trans RA (10–6 M). A
significant decrease (mean 6 SD, 75% 6 11% of control, p , 0.001)
was found after 24 h of incubation (Fig 2).
All-trans RA upregulates VEGF/VPF secretion by A431 cells
and does not affect its secretion by HaCaT cells In contrast to
what we observed for KC in primary culture, all-trans RA induced
VEGF/VPF production strongly and in a dose-dependent manner in
the epidermoid carcinoma cell line A431 (Fig 3a). The mean 6 SD
upregulation of VEGF/VPF observed in five independent experiments
was 2.2 6 0.15-fold (p , 0.01, Fig 3b). No significant effects on
VEGF/VPF protein secretion were observed for the keratinocyte cell
line HaCaT (Fig 3c).
All-trans RA downregulates VEGF/VPF mRNA expression in
KC When we examined VEGF/VPF mRNA expression in KC
exposed to 10–6 M all-trans RA, we observed a decrease to about 25%
of levels obtained in control cultures incubated with 0.01% DMSO
alone after 4 h (Fig 4). This effect was still present after 8 h. In some
experiments upregulation of VEGF/VPF mRNA was observed in KC
cultured in 0.01% DMSO, compared with those cultured in KBM
medium alone. This effect was not paralleled by increased VEGF/VPF
secretion by the cells.
The effect of all-trans RA was also studied in A431 cells. Clear
upregulation of VEGF/VPF mRNA was observed at concentrations
between 10–6 and 10–8 M after 4 h (data not shown).
DISCUSSION
In this study we demonstrate that retinoids downregulate spontaneous
and TGFα-induced VEGF/VPF mRNA and protein production in
primary cultures of human KC. VEGF/VPF secretion was reduced to
58%, 41%, and 52% by all-trans RA, 13-cis RA, and all-trans retinol,
respectively. The inhibition of VEGF/VPF release was strongest at
retinoid concentrations of 10–6 M, which can be reached during
systemic therapy (Smith et al, 1992). The baseline release of VEGF/
VPF differed among several batches of KC and among individual
experiments using the same batch, despite the fact that culture
conditions were otherwise identical. Differences in storing and shipping
of the samples and resulting different plating efficiency might account
for those deviations; however, because in each experiment retinoid-
treated KC exhibited lower levels of VEGF/VPF secretion than did
DMSO-treated control cells, regardless of the absolute amount of
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Figure 1. VEGF/VPF secretion by KC is suppressed by all-trans RA,
13-cis RA, and all-trans retinol. KC were incubated for 24 h with the
indicated concentrations of retinoids as described in Materials and Methods.
Supernatants were analyzed using a VEGF/VPF-specific ELISA. For (a), KC
were cultured in either KBM alone (black bar), KBM supplemented with
0.01% DMSO without (open bar), or different concentrations of all-trans RA
(hatched bar). Each bar represents the mean 6 SD VEGF/VPF concentration
in pg per ml of triplicate assays. In (b), KC were incubated with either 10–6 M
all-trans RA, 10–6 M 13-cis RA, or 10–6 M all-trans retinol. Each bar represents
the mean 6 SD inhibition in percentage of the DMSO control. For all-trans
RA, 13-cis RA, and all-trans retinol 13, 5, and 4, respectively, independent
experiments were carried out, and at least three of each group were run in
triplicate. *p , 0.001 (ANOVA).
VEGF/VPF, differing baseline values do not interfere with the conclu-
sions on the inhibitory effects of retinoids.
The downregulatory effect of all-trans RA on VEGF/VPF produc-
tion was also observed when KC were cultured in the presence of
TGFα, a strong inductor of this cytokine (Detmar et al, 1994). Given
that TGFα is strongly upregulated in psoriatic epidermis (Elder et al,
1989), the ability of retinoids to reduce the effects of TGFα on VEGF/
VPF production in vitro argues for its potential to interrupt the cycle
of paracrine VEGF/VPF induction in psoriasis.
In addition to psoriasis, systemic retinoids are widely used as an
effective treatment for rosacea (Plewig, 1993). The cardinal signs of
this disorder, i.e., facial edema, erythema, and telangiectasias (Plewig,
1993; Wilkin, 1994), are also highly suggestive of a pathogenic role
for VEGF/VPF. Therefore, it is tempting to speculate that the reduction
of these signs after isotretinoin treatment might be due, at least in part,
Figure 2. All-trans RA reduces TGFa-induced VEGF/VPF upregulation
by primary human KC. KC were incubated simultaneously with TGFα
(100 ng per ml) and all-trans RA (10–6M) for 24 h. Supernatants were analyzed
using a VEGF/VPF-specific ELISA. The bar represents the mean 6 SD
inhibition in percentage of control. Five individual experiments in triplicate
were carried out. *p , 0.001 (ANOVA).
to the inhibited VEGF/VPF production. We are currently investigating
the production of VEGF/VPF by KC in this disease.
Topical retinoid therapy is used to reverse some of the effects of
photoaging (Gilchrest, 1992; Kang et al, 1997). After long-term
application of tretinoin, skin architecture is dramatically changed,
and increased epidermal thickness, deposition of extracellular matrix
proteins, and increased vascularity of the dermis can be observed
(Fisher et al, 1991; Gilchrest, 1992; Griffith et al, 1995; Kang et al,
1997). These findings are at first glance contradictory to our results on
the inhibition of VEGF/VPF production by retinoids; however, the
effects of long-term retinoid application on epidermis certainly differ
from those of short-term exposure of KC in tissue culture. In addition,
topical retinoids have different effects on the epidermis than do systemic
retinoids. Whereas the former induce KC proliferation, resulting in a
thicker epidermis, the latter lead to epidermal thinning in diseases such
as psoriasis as a consequence of a decreased proliferation of KC
(Gilchrest, 1992; Griffith et al, 1995; Gottlieb et al, 1996). Thus, even
if VEGF/VPF production on a per cell base should be reduced after
topical retinoid treatment of photoaged skin, an increase in keratinocyte
numbers might lead to a relative increase in secreted growth factors,
including VEGF/VPF. Future studies will be necessary to verify this
scenario, however.
In contrast to what we observed for primary KC, no alteration of
VEGF/VPF production by retinoids was found with the KC-derived
cell line HaCaT, and VEGF/VPF mRNA and protein were even
upregulated 2-fold in A431 cells. Concerning the possible relevance
to our understanding of the therapeutic effects of retinoids, the data
obtained with the cell lines suggest that the anti-angiogenic effects of
retinoids in vivo might not be generally due to downregulated VEGF/
VPF production. As has been suggested previously, these effects may
be attributable to a direct action on endothelial cells and to the
induction of anti-angiogenic molecules instead (Lingen et al, 1996a, b).
Retinoids act by binding to retinoic acid receptors and retinoid X
receptors (for review see Chambon, 1996). These heterodimeric
receptor complexes bind to the retinoic acid responsive element within
promoter regions and stimulate the transcription of retinoid responsive
genes (Chambon, 1996). Besides transcriptional activation, retinoids can
also repress transcription, a process that is referred to as transrepression
(Chambon, 1996; Fisher and Voorhees, 1996). In contrast to transcrip-
tional activation, transrepression does not involve interaction of the
retinoic acid receptors/retinoid X receptors complex with the retinoic
acid responsive element. Rather, it depends on the transcription factor
AP-1, which is composed of c-jun and c-fos proteins (Chambon,
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Figure 3. All-trans RA upregulates VEGF/VPF secretion by A431 cells,
but not by HaCaT cells. A431 cells (a, b) or HaCaT cells (c) were incubated
in RPMI-1640 alone (black bars), or supplemented with either 0.01% DMSO
(open bars), all-trans RA (hatched bars), or TGFα (100 ng per ml, punctata
bars) for 24 h. Supernatants were analyzed using a VEGF/VPF-specific ELISA.
Bars represent mean 6 SD VEGF/VPF concentration in pg per ml. Part (a)
shows a dose-response curve with all-trans RA performed in triplicate. In (b)
and (c) each bar is the mean 6 SD level of VEGF/VPF secretion of five and
three, respectively, individual experiments performed in triplicate. The values
were compared with the Student’s t test. *p , 0.01, **p 5 0.03.
1996; Fisher and Voorhees, 1996; Karin et al, 1997), and it is thought
to be mediated either by physical interaction of retinoid receptors with
c-jun and c-fos, or, alternatively, by their competition for a possible
third binding partner (Chambon, 1996; Fisher and Voorhees, 1996).
Because the VEGF/VPF promoter contains at least one AP-1 site
(Tischer et al, 1991), transrepression may play a role in the downregul-
ation of VEGF/VPF by retinoids in KC in primary culture. This
Figure 4. All-trans RA suppresses VEGF/VPF mRNA expression in
KC. KC were incubated in KBM supplemented with 0.01% DMSO with or
without 10–6 M all-trans RA. Total RNA was isolated after 4 h and 8 h,
subjected to agarose gel electrophoresis, transferred to a nylon membrane, and
analyzed by northern hybridization for VEGF/VPF (upper panel) or GAPDH
(lower panel) mRNA expression.
assumption is supported by the observed decrease in VEGF/VPF
mRNA after retinoid treatment of KC; however, we cannot formally
exclude the possibility that reduced mRNA stability is also involved.
Because transrepression is influenced by the amount of retinoid
receptor proteins present and by the level of AP-1 activation (Chambon,
1996; Fisher and Voorhees, 1996), different levels of these molecules
in KC, HaCaT, and A431 cells may explain the different effects of
retinoids observed.
In summary, we have demonstrated that retinoids downregulate
VEGF/VPF mRNA expression and protein production in primary
culture of KC. Based on these findings we suggest that the therapeutic
action of retinoids, as observed in inflammatory skin disorders associated
with hypervascularization such as psoriasis, is due, at least in part, to
the suppression of VEGF/VPF secretion by KC.
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